An interventional study of Escitalopram (Oral antidepressant) in Depression - Major Depressive Disorder, sponsored by Peking University. Recruiting at 5 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Peking University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 108 studies testing escitalopram in Depression — 6 open to participants now, 7 under way, none of them phase 3. Escitalopram · Depression.
Among the 108 studies testing escitalopram in Depression, this one is the 36th largest by planned enrollment, is the only one that started in 2026, is one of 17 with no phase, and was the 108th registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →6 of the 108 studies testing escitalopram in Depression are open now, in 5 countries. Recruiting first, the newest first:
Poznan University of Medical Sciences · Sites in Poland
Ages 12+
Medical University of Vienna · Sites in Austria
Ages 18–65 · Healthy volunteers
Chonnam National University Hospital · Sites in Korea, Republic of
Ages 19–65
University of Cincinnati · Sites in United States
Ages 18–50
University of Cincinnati · Sites in United States
Ages 12–17
By country, each count listing its studies:
Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
108 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 10 · Phase 3 29 · Phase 4 54
First in 2001; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 107 across the 108 interventional studies. Of the 86 that completed or were terminated, 49 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 108 have an industry lead sponsor. The 10 most frequent:
Peking University is the lead sponsor of 420 studies on the registry; 124 are open to participants now.
21 studies in Depression by Peking University: 10 open now, 13 under way, none of them phase 3. Of 4 finished, 0 (0%) have results posted.
Among the 21 studies in Depression by Peking University, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2026, is one of 19 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 18th registered.
Peking University’s Depression studies by the year they started, since 2010.
3 of the studies testing escitalopram in Depression that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06675851Medical University of ViennaReward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People | 2026-12 |
| NCT07480525Peking UniversityEfficacy and Mechanisms of Escitalopram in Drug-Naïve First-Episode Major Depressive Disorder | 2026-12-31 |
| NCT07478796Poznan University of Medical SciencesTDM-Guided Treatment With SSRIs in Hospitalized Adults and Children | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 108 studies testing escitalopram in Depression, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Peking University’s 21 in Depression:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this project is to quantify the effectiveness and safety of escitalopram oxalate oral solution in the treatment of first-episode, drug-naïve patients with major depressive disorder, and to explore the mechanisms underlying its antidepressant effects using multi-omics approaches. By integrating clinical, cognitive, laboratory, imaging, genetic, and environmental data, the study aims to identify patient subgroups who are most likely to benefit from escitalopram, thereby promoting individualized and precision treatment for depression.
This multicenter, prospective, single-arm intervention study will enroll 200 adults aged 18-65 years with major depressive disorder, who will receive escitalopram oxalate oral solution for 8 weeks. Depressive symptoms, cognitive function, and adverse events will be assessed at baseline, during treatment, and after 8 weeks of treatment to evaluate efficacy and safety. Escitalopram blood concentrations will be measured at week 4 to monitor treatment adherence and support safety evaluation. Through comprehensive data collection and multimodal analysis, this project seeks to clarify the biological mechanisms of escitalopram and provide evidence to guide more precise clinical use of antidepressant therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive escitalopram oral solution as open-label monotherapy.
Drug: Escitalopram (Oral antidepressant)
Participants will receive escitalopram oral solution as open-label monotherapy.
Change from baseline in Hamilton Depression Rating Scale (HAMD)
The outcome is assessed by 17-item Hamilton Depression Rating Scale (HAMD-17) Scale. Total HAMD scores range from 0 to 24, with higher scores indicating more severe depressive symptoms. The change of HAMD from baseline to 8-week (after intervention) was used as the primary outcome.
Time frame: Week 4 and 8 of treatment duration
Change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS)
Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score. The MADRS consists of 10 clinician-rated items with a total score ranging from 0 to 60. Higher scores indicate more severe depressive symptoms.
Time frame: Week 4 and 8 of treatment duration
Response to treatment
Treatment response is defined as a ≥50% reduction from baseline in either the 17-item Hamilton Depression Rating Scale (HAMD-17) total score or the Montgomery-Åsberg Depression Rating Scale (MADRS) total score.
Time frame: Week 4 and 8 of treatment duration
Clinical Global Impression-Severity of Illness (CGI-S)
The Clinical Global Impression-Severity of Illness (CGI-S) scale is a clinician-rated measure of illness severity ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Higher scores indicate greater illness severity.
Time frame: Baseline; Week 4 and 8 of treatment duration
Change from baseline in C-BCT score
Change from baseline in the Cognitive Bias Questionnaire (C-BCT) T-score. The C-BCT score is standardized as a T-score ranging from 0 to 100. Higher T-scores indicate greater cognitive function.
Time frame: Week 4 and 8 of treatment duration
Change from baseline in Hamilton Anxiety Rating Scale (HAMA)
Change from baseline in the Hamilton Anxiety Rating Scale (HAMA) total score. The HAMA contains 14 items with a total score ranging from 0 to 56. Higher scores indicate more severe anxiety symptoms.
Time frame: Week 4 and 8 of treatment duration
Treatment Emergent Symptom Scale (TESS)
The Treatment Emergent Symptom Scale (TESS) is used to assess adverse events during treatment. The total score ranges from 0 to 350 (please specify according to the version used). Higher scores indicate greater severity of treatment-emergent adverse effects.
Time frame: Baseline; Week 4 and 8 of treatment duration
Escitalopram Therapeutic drug monitoring
Time frame: Week 4 of treatment duration
Change from baseline in Snaith-Hamilton Pleasure Scale (SHAPS)
Change from baseline in the Snaith-Hamilton Pleasure Scale (SHAPS) total score. The SHAPS consists of 14 items with a total score ranging from 0 to 56. Higher scores indicate greater anhedonia.
Time frame: Week 4 and 8 of treatment duration
The Temporal Experience of Pleasure Scale (TEPS)
Change from baseline in the Temporal Experience of Pleasure Scale (TEPS) total score. The score ranges from 0 to 100 depending on the version used. Higher scores indicate greater hedonic capacity.
Time frame: Week 4 and 8 of treatment duration
Childhood Trauma Questionnaire (CTQ)
The Childhood Trauma Questionnaire (CTQ) assesses childhood maltreatment experiences. The total score ranges from 28 to 140. Higher scores indicate more severe childhood trauma.
Time frame: Baseline
Change from baseline in Ruminative Responses Scale (RRS)
Change from baseline in the Ruminative Responses Scale (RRS) total score. The total score ranges from 22 to 88. Higher scores indicate greater rumination.
Time frame: Week 4 and 8 of treatment duration
Change from baseline in Pittsburgh Sleep Quality Index (PSQI)
Change from baseline in the Pittsburgh Sleep Quality Index (PSQI) global score. The total score ranges from 0 to 21. Higher scores indicate poorer sleep quality.
Time frame: Week 4 and 8 of treatment duration
Change from baseline in Connor-Davidson Resilience Scale (CD-RISC)
Change from baseline in the Connor-Davidson Resilience Scale (CD-RISC) total score. The total score ranges from 0 to 100 (25-item version). Higher scores indicate greater psychological resilience.
Time frame: Week 4 and 8 of treatment duration
Brain imaging features
Acquisition was performed by magnetic resonance imaging
Time frame: Week 0 and 8 of treatment duration
Change from baseline in liver function biomarkers
Change from baseline in alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Both biomarkers are measured in IU/L.
Time frame: Baseline, Week 4, and Week 8 of treatment duration
Change from baseline in lipid biomarkers
Change from baseline in total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). All biomarkers are measured in mmol/L.
Time frame: Baseline, Week 4, and Week 8 of treatment duration
Change from baseline in fasting blood glucose
Change from baseline in fasting blood glucose, measured in mmol/L.
Time frame: Baseline, Week 4, and Week 8 of treatment duration
Change from baseline in glycated hemoglobin (HbA1c)
Change from baseline in glycated hemoglobin (HbA1c), measured as percentage (%).
Time frame: Baseline, Week 4, and Week 8 of treatment duration
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 9 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Escitalopram